IPH4102

Phase 2Biologic

IInnate Pharma

IPH4102 is one of 80 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

IPH4102

IInnate Pharma

Phase 2

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Active, not recruiting·IInnate Pharma·Phase 2·NCT03902184·170 enrolled

Cutaneous T-cell lymphoma1 trial

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Completed·IInnate Pharma·Phase 1·NCT02593045·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IPH4102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPH4102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPH4102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innate Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IInnate Pharma

IPH4102

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

Cutaneous T-cell lymphoma1 trial

References

Drug Info

Quick Facts

Related News